

ATTORNEY DOCKET NO.:
CUSTOMER NUMBER:

T00462-0003-WO-US
000027155

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re patent application of:

GUTHRIE and KUROWSKA

Serial No.:	10/697,563	Group Art Unit:	NOT YET SPECIFIED
Filed:	October 31, 2003	Examiner:	NOT YET SPECIFIED
Title:	POLYMETHOXYLATED FLAVONES FOR TREATING INSULIN RESISTANCE		

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty to disclose under 37 CFR §1.56, Applicant submits herewith a Form PTO/SB/08A listing references of which the Applicant is aware and which are brought to the attention of the Examiner. In accordance with 37 CFR §1.98(a)(2), a copy of each document listed in the enclosed Form PTO/SB/08A is submitted herewith excluding U.S. patent references.

U.S. patent references are not enclosed pursuant to the Office's waiver (published in the Official Gazette - August 5, 2003) of such requirement for all U.S. national patent applications and for all international applications that have entered the national stage under 35 USC 371 filed after June 30, 2003.

Pursuant to 35 USC §120, this application relies on the earlier filing date(s) of the following prior application(s):

Serial Number

PCT/CA02/00662

60/287,703

Filing Date

May 2, 2002

May 2, 2001


The filing of this IDS shall not be construed as a representation that a search has been made, an admission that the information cited is, or is considered to be, material for patentability, or that no other material information exists. This filing shall not be construed as an admission against interest in any matter.

This IDS is submitted pursuant to 37 CFR §1.97(b) and, accordingly, no fee is believed to be due for consideration of the documents submitted herewith.

Applicant respectfully requests consideration of the items listed and requests the Examiner to return a copy of the attached Form PTO/SB/08A after being marked as being considered by the Examiner.

Respectfully submitted,

Date:

APRIL 29, 2004

Santosh K. Chari
Registration No. 41,477
Agent for Applicant

McCarthy Tétrault
Suite 4700, P.O. Box 48
Toronto Dominion Bank Tower
Toronto, Ontario M5K 1E6, Canada

Tel: 416 362-1812
Fax: 416 601-8454

Complete if Known

Application Number	10/697,563
Filing Date	October 31, 2003
First Named Inventor	GUTHRIE
Art Unit	NOT YET SPECIFIED
Examiner Name	NOT YET SPECIFIED
Attorney Docket Number	T00462-0003-WO-US

(use as many sheets as necessary)

Sheet

1

of

2

Attorney Docket Number

T00462-0003-WO-US

[illegible][illegible]

Date Considered	
-----------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/697,563	
			Filing Date	October 31, 2003	
			First Named Inventor	GUTHRIE	
			Art Unit	NOT YET SPECIFIED	
			Examiner Name	NOT YET SPECIFIED	
Sheet	2	of	2	Attorney Docket Number	T00462-0003-WO-US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROBBINS, Effect of Flavonoids on Survival Time of Rats Fed Thombogenic or Atherogenic Regimens, Journal of Atherosclerosis Research, volume 7, 1967, pages 3-10, Elsevier Publishing Company, The Netherlands.	
		GUTHRIE et al, In Vitro Studies on Anti-Cancer and Cholesterol-Lowering Activities of Citrus Flavonoids and Ilinonoids", FASEB Journal, March 15, 2000, page A564: Abstract, vol. 14, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.	
		KUROWSKA et al, Regulation of Lipoprotein Metabolism in HEPG2 Cells by Citrus Flavonoids", American Chemical Society, abstract, March 2000, vol. 219, The National Meeting, American Chemical Society, Washington, D.C., USA.	
		KUROWSKA et al, Hypolipidemic activities of tangeretin a flavonoid from tangerine in vitro and in vivo, Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001, March 31-April 4, 2001, Abstract, Orlando, Florida, USA.	
		KUROWSKA et al., Tangeretin, a Citrus Flavonoid, reduces metabolic abnormalities associated with insulin resistance, FASEB Journal, March 20, 2002, page A648: Abstract, volume 16, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.	
		MERCK RESEARCH LABORATORIES, The Merck Manual of Diagnosis and Therapy, 1999, page 166 right-hand column, page 167 left-hand column line 4, Merck Research Laboratories, Whitehouse Station, N.J., USA.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.